ABOUT THIS PODCAST 🔗

Update frequency:
daily
Average audio length:
22 minutes
Guest interviews
English
United States
408 episodes
since Oct. 6, 2021
episodic

LATEST EPISODE 🔗

Send us Fan Mail Enlarged perivascular spaces, the fluid-filled channels around small blood vessels in the brain, show up on routine MRI. This study of 307 people with cognitive impairment from a Seoul dementia cohort asked whether amyloid and blood vessel disease leave different patterns of these …

SEARCH PAST EPISODES

Search past episodes of The Longevity Podcast: Alzheimer's and Brain Health Research.

PREVIOUS EPISODES

Send us Fan Mail How do clinicians tell mild dementia from moderate dementia? This study tested the Functional Activities Questionnaire, an informant-based checklist of everyday tasks, in more than 34,000 people from the US NACC database and confirmed the results in the ADNI and FTLDNI cohorts. A s…
Send us Fan Mail Using amyloid and tau PET scans from two US cohorts, ADNI and the Harvard Aging Brain Study, researchers estimated how long it takes to go from amyloid positivity to tau positivity. That interval varied widely and was shorter in APOE4 carriers, women, and people who became amyloid …
Send us Fan Mail A gut bacterial compound called imidazole propionate (ImP) is linked to Alzheimer's-related brain changes and faster cognitive decline in a large Wisconsin cohort, with mouse and cell studies pointing to barrier and tau pathways. Researchers measured blood ImP in nearly 1,200 …
Send us Fan Mail A Mendelian randomization study of plasma proteins, structural MRI measures, and Alzheimer's disease risk found 12 neuroimaging metrics and 1,633 proteins with causal ties to AD. Brain imaging also mediated about 67% of the link between the immune-related protein PTPRC and Alz…
Send us Fan Mail A China-wide survey of 1,057 older adults with Alzheimer's or related cognitive impairment found 73.5% had at least one safety incident in the past year, and over a third reported three or more. Medication errors and verbal aggression were the most common, followed by falls an…
Send us Fan Mail A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world…
Send us Fan Mail A letter responds to a large review of public dementia risk awareness, arguing that recognizing a risk factor is not the same as knowing what to do about it. The authors urge surveys to measure actionable knowledge, whether risks are personal habits or policy problems, and to separ…
Send us Fan Mail When Europe approved donanemab and lecanemab, the label was narrower than the trials: early Alzheimer's, APOE ε4 non-carriers or heterozygotes, plus extra exclusions. This editorial walks through why EU-eligible subgroup analyses matter—and how Jessen's TRAILBLAZER-ALZ 2 …
Send us Fan Mail How does toxic Tau leave the brain? In this editorial, Vincent Prévot and colleagues spotlight tanycytes—specialized cells lining the third ventricle that shuttle Tau from cerebrospinal fluid into the blood. In Alzheimer's disease these cells are fragmented and their transport…
Disclaimer: The podcast and artwork embedded on this page are from Dung Trinh, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.